Clinical Trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 2 changes
notable Trial sites expanded: 780 -> 783 locations 2026-08-06
notable Trial sites expanded: 777 -> 781 locations 2026-04-08
Trial Details
NCT Number NCT02523014
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Conditions Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Enrollment 124 participants
Start Date 2015-09-28
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05